Details of the Drug

General Information of Drug (ID: DM6W8V5)

Drug Name

Lisdexamfetamine

Synonyms

NRP104; Lisdexamfetamine (INN); Vyvanse (TN)

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

263.38

Topological Polar Surface Area (xlogp)

1.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-4.4 h [3]
Clearance: The clearance of drug is 0.7 L/h/kg [4]
Elimination: After the oral administration of a 70mg dose of radiolabeled lisdexamfetamine dimesylate to six healthy subjects, about 96% of the oral dose radioactivity was recovered in the urine and only 0.3% recovered in the feces [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [3]
Metabolism: The drug is metabolized to the active metabolite d-amphetamine occurs primarily in the blood through enzymatic cleavage [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.6 L/kg [6]

Chemical Identifiers

Formula: C15H25N3O
IUPAC Name: (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
Canonical SMILES: C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N
InChI: InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
InChIKey: VOBHXZCDAVEXEY-JSGCOSHPSA-N

Cross-matching ID

PubChem CID: 11597698
ChEBI ID: CHEBI:135925
CAS Number: 608137-32-2
DrugBank ID: DB01255
TTD ID: D00DEF
VARIDT ID: DR00003
INTEDE ID: DR0963
ACDINA ID: D00369

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Trace amine-associated receptor-1 (TAAR1)	TTIU98M	TAAR1_HUMAN	Modulator	[7], [8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Attention deficit hyperactivity disorder

ICD Disease Classification

6A05.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Trace amine-associated receptor-1 (TAAR1)	DTT	TAAR1	6.12E-01	-0.01	-0.06
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lisdexamfetamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Lisdexamfetamine caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[35]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[36]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Midostaurin.	Acute myeloid leukaemia [2A60]	[37]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Arn-509.	Acute myeloid leukaemia [2A60]	[37]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[37]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Oliceridine.	Acute pain [MG31]	[37]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Lisdexamfetamine and Ivabradine.	Angina pectoris [BA40]	[37]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Dronedarone.	Angina pectoris [BA40]	[38]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[39]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Posaconazole.	Aspergillosis [1F20]	[37]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Levalbuterol.	Asthma [CA23]	[40]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Pirbuterol.	Asthma [CA23]	[41]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Lisdexamfetamine and Droxidopa.	Autonomic nervous system disorder [8D87]	[42]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Retigabine.	Behcet disease [4A62]	[37]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Eribulin.	Breast cancer [2C60-2C6Y]	[37]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Lapatinib.	Breast cancer [2C60-2C6Y]	[37]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Bosutinib.	Breast cancer [2C60-2C6Y]	[37]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[43]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Lisdexamfetamine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[41]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[40]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Lisdexamfetamine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[41]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[41]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Probucol.	Coronary atherosclerosis [BA80]	[37]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Pasireotide.	Cushing syndrome [5A70]	[38]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Osilodrostat.	Cushing syndrome [5A70]	[37]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Lisdexamfetamine and Esketamine.	Depression [6A70-6A7Z]	[44]
SODIUM CITRATE	DMHPD2Y	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Lisdexamfetamine caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[35]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[38]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Deutetrabenazine.	Dystonic disorder [8A02]	[37]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Ingrezza.	Dystonic disorder [8A02]	[37]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Solifenacin.	Functional bladder disorder [GC50]	[37]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[37]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Lisdexamfetamine caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Lisdexamfetamine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[38]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Lisdexamfetamine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[38]
R0-93877	DMM4U9G	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and R0-93877.	Irritable bowel syndrome [DD91]	[37]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Ceritinib.	Lung cancer [2C25]	[38]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Osimertinib.	Lung cancer [2C25]	[45]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Selpercatinib.	Lung cancer [2C25]	[37]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Lumefantrine.	Malaria [1F40-1F45]	[44]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Hydroxychloroquine.	Malaria [1F40-1F45]	[46]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[37]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Vemurafenib.	Melanoma [2C30]	[38]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and LGX818.	Melanoma [2C30]	[47]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Panobinostat.	Multiple myeloma [2A83]	[48]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Lisdexamfetamine and Siponimod.	Multiple sclerosis [8A40]	[44]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Lisdexamfetamine and Fingolimod.	Multiple sclerosis [8A40]	[38]
Ozanimod	DMT6AM2	Moderate	Increased risk of hyperpyrexia by the combination of Lisdexamfetamine and Ozanimod.	Multiple sclerosis [8A40]	[49]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Romidepsin.	Mycosis fungoides [2B01]	[37]
Vorinostat	DMWMPD4	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Vorinostat.	Mycosis fungoides [2B01]	[37]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[38]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Entrectinib.	Non-small cell lung cancer [2C25]	[44]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Lofexidine.	Opioid use disorder [6C43]	[38]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Rucaparib.	Ovarian cancer [2C73]	[37]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Triclabendazole.	Parasitic worm infestation [1F90]	[37]
Safinamide	DM0YWJC	Major	Additive hypertensive effects by the combination of Lisdexamfetamine and Safinamide.	Parkinsonism [8A00]	[49]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Lisdexamfetamine and Rasagiline.	Parkinsonism [8A00]	[49]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Pimavanserin.	Parkinsonism [8A00]	[50]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[51]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Lefamulin.	Pneumonia [CA40]	[52]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Degarelix.	Prostate cancer [2C82]	[37]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and ABIRATERONE.	Prostate cancer [2C82]	[37]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Enzalutamide.	Prostate cancer [2C82]	[37]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Relugolix.	Prostate cancer [2C82]	[37]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Lisdexamfetamine when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[53]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Iloperidone.	Schizophrenia [6A20]	[38]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Amisulpride.	Schizophrenia [6A20]	[54]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Asenapine.	Schizophrenia [6A20]	[38]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[38]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[38]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[37]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Pitolisant.	Somnolence [MG42]	[37]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[37]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Lenvatinib.	Thyroid cancer [2D10]	[37]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Lisdexamfetamine and Cabozantinib.	Thyroid cancer [2D10]	[37]
-----------


⏷ Show the Full List of 77 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lisdexamfetamine 30 mg capsule	30 mg	Oral Capsule	Oral
Lisdexamfetamine 40 mg capsule	40 mg	Oral Capsule	Oral
Lisdexamfetamine 70 mg capsule	70 mg	Oral Capsule	Oral
Lisdexamfetamine 10 mg capsule	10 mg	Oral Capsule	Oral
Lisdexamfetamine 20 mg capsule	20 mg	Oral Capsule	Oral
Lisdexamfetamine 10 mg tablet	10 mg	Chewable Tablet	Oral
Lisdexamfetamine 20 mg tablet	20 mg	Chewable Tablet	Oral
Lisdexamfetamine 30 mg tablet	30 mg	Chewable Tablet	Oral
Lisdexamfetamine 40 mg tablet	40 mg	Chewable Tablet	Oral
Lisdexamfetamine 50 mg tablet	50 mg	Chewable Tablet	Oral
Lisdexamfetamine 60 mg tablet	60 mg	Chewable Tablet	Oral
Lisdexamfetamine 50 mg capsule	50 mg	Oral Capsule	Oral
Lisdexamfetamine 60 mg capsule	60 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7213).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021977.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Kanamori T, Iwata YT, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, Inoue H: Metabolism of Butyrylfentanyl in Fresh Human Hepatocytes: Chemical Synthesis of Authentic Metabolite Standards for Definitive Identification. Biol Pharm Bull. 2019;42(4):623-630. doi: 10.1248/bpb.b18-00765.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
8	Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class. Bioorg Med Chem. 2011 Dec 1;19(23):7044-8.
9	Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27.
10	Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
11	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
12	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
13	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
17	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
18	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
19	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
20	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
21	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
22	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
23	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
24	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
25	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
26	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
27	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
28	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
29	Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
30	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
31	Clinical pipeline report, company report or official report of Roche.
32	Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
33	The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
34	The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39.
35	Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80. [PMID: 4729903]
36	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
37	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38	Canadian Pharmacists Association.
39	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
40	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
41	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
42	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
43	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Cerner Multum, Inc. "Australian Product Information.".
45	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
46	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
47	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
48	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
49	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
50	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
51	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
52	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
53	Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
54	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.